Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the generic erosion of market leading therapies will constrain the Parkinson's disease drug market, resulting in an annual market growth rate of only 1.4 percent through 2017 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The new Pharmacor report entitled Parkinson's Disease finds that the generic erosion of Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol, GlaxoSmithKline's Requip, Teva/Lundbeck's Agilect/Azilect and Novartis/Orion's Stalevo will cause sales of these agents to decline over the next decade, despite their increased use. The key agents in the dopamine agonist drug class, Requip and Mirapex/Mirapexin/Sifrol, will be most significantly affected by near-term generic erosion through 2012.

The modest growth of the Parkinson's disease drug market over the next decade will be driven by the arrival of once-daily formulations of current market leading dopamine agonists, GlaxoSmithKline/SkyePharma's Requip XL/CR/LP and Boehringer Ingelheim's pramipexole ER. Growth will also be driven by the launch of two new therapies-Merck Serono/Newron's safinamide and Solvay's pardoprunox-and by increases in drug-treatment rates due to aging populations in the world's major pharmaceutical markets.

"The greatest unmet need in Parkinson's disease treatment, the need for a disease-modifying therapy, will remain unfulfilled over the next 10 years," said Sami Fam, Ph.D., analyst at Decision Resources. "Key opinion leaders in this therapeutic area unanimously agree that the most critical need is for drugs that can act on the pathological mechanisms of Parkinson's disease and provide neuroprotection and/or neurorestoration. Critical to addressing this unmet need will be a better understanding of the cellular mechanisms that underlie the pathology of Parkinson's disease."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Golimumab and Actemra Will Be Two of the Most Successful Emerging Novel Agents in the Rheumatoid Arthritis Drug Treatment Market

View Now